Literature DB >> 27116978

Large-scale assessment of the gliomasphere model system.

Dan R Laks1, Thomas J Crisman1, Michelle Y S Shih1, Jack Mottahedeh1, Fuying Gao1, Jantzen Sperry1, Matthew C Garrett1, William H Yong1, Timothy F Cloughesy1, Linda M Liau1, Albert Lai1, Giovanni Coppola1, Harley I Kornblum2.   

Abstract

BACKGROUND: Gliomasphere cultures are widely utilized for the study of glioblastoma (GBM). However, this model system is not well characterized, and the utility of current classification methods is not clear.
METHODS: We used 71 gliomasphere cultures from 68 individuals. Using gene expression-based classification, we performed unsupervised clustering and associated gene expression with gliomasphere phenotypes and patient survival.
RESULTS: Some aspects of the gene expression-based classification method were robust because the gliomasphere cultures retained their classification over many passages, and IDH1 mutant gliomaspheres were all proneural. While gene expression of a subset of gliomasphere cultures was more like the parent tumor than any other tumor, gliomaspheres did not always harbor the same classification as their parent tumor. Classification was not associated with whether a sphere culture was derived from primary or recurrent GBM or associated with the presence of EGFR amplification or rearrangement. Unsupervised clustering of gliomasphere gene expression distinguished 2 general categories (mesenchymal and nonmesenchymal), while multidimensional scaling distinguished 3 main groups and a fourth minor group. Unbiased approaches revealed that PI3Kinase, protein kinase A, mTOR, ERK, Integrin, and beta-catenin pathways were associated with in vitro measures of proliferation and sphere formation. Associating gene expression with gliomasphere phenotypes and patient outcome, we identified genes not previously associated with GBM: PTGR1, which suppresses proliferation, and EFEMP2 and LGALS8, which promote cell proliferation.
CONCLUSIONS: This comprehensive assessment reveals advantages and limitations of using gliomaspheres to model GBM biology, and provides a novel strategy for selecting genes for future study.
© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  The Cancer Genome Atlas; brain tumor stem cell; cancer stem cell; glioma; neurosphere

Mesh:

Year:  2016        PMID: 27116978      PMCID: PMC5035518          DOI: 10.1093/neuonc/now045

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  34 in total

Review 1.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

2.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

3.  Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.

Authors:  David A Nathanson; Beatrice Gini; Jack Mottahedeh; Koppany Visnyei; Tomoyuki Koga; German Gomez; Ascia Eskin; Kiwook Hwang; Jun Wang; Kenta Masui; Andres Paucar; Huijun Yang; Minori Ohashi; Shaojun Zhu; Jill Wykosky; Rachel Reed; Stanley F Nelson; Timothy F Cloughesy; C David James; P Nagesh Rao; Harley I Kornblum; James R Heath; Webster K Cavenee; Frank B Furnari; Paul S Mischel
Journal:  Science       Date:  2013-12-05       Impact factor: 47.728

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.

Authors:  Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

6.  EFEMP2 is upregulated in gliomas and promotes glioma cell proliferation and invasion.

Authors:  Long Wang; Qianxue Chen; Zhibiao Chen; Daofeng Tian; Haitao Xu; Qiang Cai; Baohui Liu; Gang Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Authors:  Heidi S Phillips; Samir Kharbanda; Ruihuan Chen; William F Forrest; Robert H Soriano; Thomas D Wu; Anjan Misra; Janice M Nigro; Howard Colman; Liliana Soroceanu; P Mickey Williams; Zora Modrusan; Burt G Feuerstein; Ken Aldape
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

Review 8.  Brain tumor stem cells as therapeutic targets in models of glioma.

Authors:  Dan Richard Laks; Koppany Visnyei; Harley Ian Kornblum
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

9.  EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.

Authors:  H Feng; B Hu; K Vuori; J N Sarkaria; F B Furnari; W K Cavenee; S-Y Cheng
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

10.  Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK).

Authors:  Jingyan Luo; Xiaoxiao Wang; Zhibo Xia; Lixuan Yang; Zhiming Ding; Shiyuan Chen; Bingquan Lai; Nu Zhang
Journal:  Mol Biol Cell       Date:  2014-11-26       Impact factor: 4.138

View more
  30 in total

1.  The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma.

Authors:  Kruttika Bhat; Mohammad Saki; Erina Vlashi; Fei Cheng; Sara Duhachek-Muggy; Claudia Alli; Garrett Yu; Paul Medina; Ling He; Robert Damoiseaux; Matteo Pellegrini; Nathan R Zemke; Phioanh Leia Nghiemphu; Timothy F Cloughesy; Linda M Liau; Harley I Kornblum; Frank Pajonk
Journal:  Proc Natl Acad Sci U S A       Date:  2020-05-01       Impact factor: 11.205

2.  Reactive species balance via GTP cyclohydrolase I regulates glioblastoma growth and tumor initiating cell maintenance.

Authors:  Anh Nhat Tran; Kiera Walker; David G Harrison; Wei Chen; James Mobley; Lauren Hocevar; James R Hackney; Randee S Sedaka; Jennifer S Pollock; Matthew S Goldberg; Dolores Hambardzumyan; Sara J Cooper; Yancey Gillespie; Anita B Hjelmeland
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

3.  A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.

Authors:  Prakash Chinnaiyan; Minhee Won; Patrick Y Wen; Amyn M Rojiani; Maria Werner-Wasik; Helen A Shih; Lynn S Ashby; Hsiang-Hsuan Michael Yu; Volker W Stieber; Shawn C Malone; John B Fiveash; Nimish A Mohile; Manmeet S Ahluwalia; Merideth M Wendland; Philip J Stella; Andrew Y Kee; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

4.  Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.

Authors:  Rajendra P Pangeni; Zhou Zhang; Angel A Alvarez; Xuechao Wan; Namratha Sastry; Songjian Lu; Taiping Shi; Tianzhi Huang; Charles X Lei; C David James; John A Kessler; Cameron W Brennan; Ichiro Nakano; Xinghua Lu; Bo Hu; Wei Zhang; Shi-Yuan Cheng
Journal:  Epigenetics       Date:  2018-08-06       Impact factor: 4.528

5.  A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma.

Authors:  Dan R Laks; Juan A Oses-Prieto; Alvaro G Alvarado; Jonathan Nakashima; Shreya Chand; Daniel B Azzam; Ankur A Gholkar; Jantzen Sperry; Kirsten Ludwig; Michael C Condro; Serli Nazarian; Anjelica Cardenas; Michelle Y S Shih; Robert Damoiseaux; Bryan France; Nicholas Orozco; Koppany Visnyei; Thomas J Crisman; Fuying Gao; Jorge Z Torres; Giovanni Coppola; Alma L Burlingame; Harley I Kornblum
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

6.  Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.

Authors:  Weikun Xiao; Rongyu Zhang; Alireza Sohrabi; Arshia Ehsanipour; Songping Sun; Jesse Liang; Christopher M Walthers; Lisa Ta; David A Nathanson; Stephanie K Seidlits
Journal:  Cancer Res       Date:  2017-12-27       Impact factor: 12.701

7.  MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.

Authors:  Tianzhi Huang; Xuechao Wan; Angel A Alvarez; C David James; Xiao Song; Yongyong Yang; Namratha Sastry; Ichiro Nakano; Erik P Sulman; Bo Hu; Shi-Yuan Cheng
Journal:  Autophagy       Date:  2019-01-31       Impact factor: 16.016

8.  Inhibition of Nucleotide Synthesis Targets Brain Tumor Stem Cells in a Subset of Glioblastoma.

Authors:  Dan R Laks; Lisa Ta; Thomas J Crisman; Fuying Gao; Giovanni Coppola; Caius G Radu; David A Nathanson; Harley I Kornblum
Journal:  Mol Cancer Ther       Date:  2016-03-29       Impact factor: 6.261

9.  Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.

Authors:  Yuyu He; Jie Li; Tomoyuki Koga; Jun Ma; Sanjay Dhawan; Yuta Suzuki; Frank Furnari; Varun V Prabhu; Joshua E Allen; Clark C Chen
Journal:  Neuro Oncol       Date:  2021-03-25       Impact factor: 12.300

10.  An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability.

Authors:  Saad Sheikh; Deeksha Saxena; Xiaobing Tian; Ahmad Amirshaghaghi; Andrew Tsourkas; Steven Brem; Jay F Dorsey
Journal:  Mol Cancer Res       Date:  2019-01-14       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.